Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost

This publication has 35 references indexed in Scilit:

• An Economic Evaluation of Activated Protein C Treatment for Severe Sepsis
  New England Journal of Medicine, 2002
• A Proportional Hazards Model for the Subdistribution of a Competing Risk
  Journal of the American Statistical Association, 1999
• The Italian SEPSIS study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock
  Intensive Care Medicine, 1995
• Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis
  JAMA, 1995
• A review of cost studies of intensive care units
  Critical Care Medicine, 1995
• A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study
  JAMA, 1993
• Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients
  Published by American Medical Association (AMA) ,1993
• Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent
  JAMA, 1991
• APACHE II
  Critical Care Medicine, 1985
• Therapeutic Intervention Scoring System
  Critical Care Medicine, 1983